CLINICAL TRIALS PROFILE FOR AVP-786
✉ Email this page to a colleague
Clinical Trials for AVP-786
| Trial ID | Title | Status | Sponsor | Phase | Summary |
|---|---|---|---|---|---|
| NCT01787747 ↗ | Pharmacokinetics (PK) and Tolerability of AVP-786 in Healthy Volunteers | Completed | Avanir Pharmaceuticals | Phase 1 | To assess the single- and multiple-dose pharmacokinetic (PK), safety and tolerability of AVP-786 in healthy volunteers. |
| NCT02153502 ↗ | Efficacy, Safety, and Tolerability Study of AVP-786 as an Adjunctive Therapy in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment | Completed | Avanir Pharmaceuticals | Phase 2 | The objectives of this 10-week study are to evaluate the efficacy, safety, and tolerability of AVP 786 as an adjunctive therapy compared with placebo in patients with major depressive disorder (MDD) who have shown an inadequate response to standard antidepressant treatment. A secondary objective of this study is to assess the pharmacokinetics (PK) of AVP-786 and potential correlations with pharmacodynamic effects. |
| NCT02174822 ↗ | A Phase 1, Drug Interaction Study Between AVP-786 and Paroxetine and Between AVP-786 and Duloxetine in Healthy Subjects | Completed | Avanir Pharmaceuticals | Phase 1 | To assess steady state pharmacokinetics (PK), safety and tolerability between AVP-786 (deuterated [d6] dextromethorphan hydrobromide [DM]/quinidine sulfate [Q]) and paroxetine and between AVP-786 and duloxetine. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for AVP-786
Condition Name
Clinical Trial Locations for AVP-786
Trials by Country
Clinical Trial Progress for AVP-786
Clinical Trial Phase
Clinical Trial Sponsors for AVP-786
Sponsor Name
